Overview

The Efficacy and Safety of Apatinib Monotherapy in Maintenance Treatment of Extensive-stage Small-cell Lung Cancer

Status:
Unknown status

Trial end date:
2020-03-01

Target enrollment:

Participant gender:

Summary

52 patients with extensive-stage small-cell lung cancer and without progression after completing chemotherapy, will receive apatinib monotherapy as maintenance therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Junling Li

Treatments:

Apatinib